Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin

Journal of Clinical Pharmacology

Volumn 51, Issue 1, 2011, Pages 84-92

  Krishna, Gopal ^a   Vickery, Donna ^b   Ma, Lei ^a   Yu, Xin ^a   Noren, Carl ^a   Power, Edward ^c   Beresford, Eric ^a   Medlock, Matthew ^d  

^a Forest Research Institute ^*  (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

^d Pharmaceutical Product Development   (United States)

Author keywords

antifungal; caspofungin; drug interaction; echinocandin; micafungin; pharmacokinetics; Posaconazole

Indexed keywords

CASPOFUNGIN; MICAFUNGIN; POSACONAZOLE;

ADULT; ANEMIA; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL LABORATORY; DIARRHEA; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY THROAT; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RASH; STEADY STATE; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; DRUG INTERACTIONS; ECHINOCANDINS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOPEPTIDES; MALE; TRIAZOLES; YOUNG ADULT;

EID: 78650820590     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009360982     Document Type: Article

References (36)

1. Cornely OA, Maertens J., Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 ; 356: 348-359.
2. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 ; 356: 335-347.
3. Walsh TJ, Raad I., Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007 ; 44: 2-12.
4. Raad II, Hachem RY, Herbrecht R., et al. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006 ; 42: 1398-1403.
5. Wexler D., Courtney R., Richards W., Banfield C., Lim J., Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004 ; 21: 645-653.
6. Ghosal A., Hapangama N., Yuan Y., et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004 ; 32: 267-271.
7. Krieter P., Flannery B., Musick T., Gohdes M., Martinho M., Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother. 2004 ; 48: 3543-3551.
8. Saad AH, DePestel DD, Carver PL Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006 ; 26: 1730-1744.
9. Caspofungin (Cancidas) for aspergillosis. Med Lett Drugs Ther. 2001 ; 43: 58-59.
10. CANCIDAS (caspofungin acetate) for injection [prescribing information]. Whitehouse Station, NJ: Merck & Co ; July 2007.
11. Micafungin (Mycamine) for fungal infections. Med Lett Drugs Ther. 2005 ; 47: 51-52.
12. Mycamine (micafungin sodium) for injection [prescribing information]. Deerfield, Ill: Astellas Pharma US ; June 2006.
13. Lipp HP Antifungal agents-clinical pharmacokinetics and drug interactions. Mycoses. 2008 ; 51 (suppl 1). 7-18.
14. Cross SA, Scott LJ Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections. Drugs. 2008 ; 68: 2225-2255.
15. Bellmann R. Clinical pharmacokinetics of systematically administered antimycotics. Curr Clin Pharmacol. 2007 ; 2: 37-58.
16. Pfaller MA, Diekema DJ Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007 ; 20: 133-163.
17. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008 ; 46: 327-360.
18. Rieger CT, Ostermann H., Kolb HJ, et al. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients. Ann Hematol. 2008 ; 87: 915-922.
19. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006 ; 53: 337-349. 20. Chen Sca, Sorrell TC Antifungal agents. Med J Aust. 2007 ; 187: 404-409.
20. Krishna G., Moton A., Ma L., Medlock MM, McLeod J. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009 ; 53: 958-966.
21. Bi S., Schwartz MS, Desai RB, Miller AR, Matuszewski BK A semi-automated procedure for the determination of caspofungin in human plasma using solid-phase extraction and HPLC with fluorescence detection using secondary ionic interactions to obtain a highly purified extract. J Liq Chromatogr Relat Technol. 2005 ; 28: 2895-2908.
22. Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol. 2005 ; 45: 1145-1152.
23. Shen JX, Krishna G., Hayes RN A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal. 2007 ; 43: 228-236.
24. Courtney R., Pai S., Laughlin M., Lim J., Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003 ; 47: 2788-2795.
25. Krishna G., Sansone-Parsons A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Paper presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition; December 3-7, 2006 ; Anaheim, Calif.
26. Wilson DT, Drew RH, Perfect JR Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia. 2009 ; 168: 313-327.
27. Reed C., Bryant R., Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008 ; 47: 364-371.
28. Marr KA, Boeckh M., Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004 ; 39: 797-802.
29. Schilling A., Seibold M., Mansmann V., Gleissner B. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/ posaconazole therapy. Med Mycol. 2008: 46: 79-83.
30. Perkhofer S., Lass-Flörl C. Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination. Exp Opin Invest Drugs. 2009 ; 18: 1393-1404.
31. Manavathu EK, Alangaden GJ, Chandrasekar PH Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother. 2003 ; 51: 1423-1425.
32. Shalit I., Shadkchan Y., Samra Z., Osherov N. In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob Agents Chemother. 2003 ; 47: 1416-1418.
33. Guembe M., Guinea J., Pelaez T., Torres-Narbona M., Bouza E. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother. 2007 ; 51: 3457-3458.
34. Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, Redding SW In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob Agents Chemother. 2005 ; 49: 3544-3545.
35. Cacciapuoti A., Halpern J., Mendrick C., Norris C., Patel R., Loebenberg D. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother. 2006 ; 50: 2587-2590.
36. NOXAFIL (posaconazole) oral suspension [prescribing information]. Kenilworth, NJ: Schering Corporation ; May 2008.